{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:42:34Z","timestamp":1777430554521,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.euf.2017.03.015","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T15:45:22Z","timestamp":1491666322000},"page":"874-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate"],"prefix":"10.1016","volume":"4","author":[{"given":"Giuseppe","family":"Di Lorenzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Carten\u00ec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piera","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Buonerba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2017.03.015_bib0005","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2017.03.015_bib0010","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/14737159.2016.1240031","article-title":"Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer","volume":"16","author":"Buonerba","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.euf.2017.03.015_bib0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2011.39.1300","article-title":"Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer","volume":"30","author":"Nelson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.03.015_bib0025","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.03.015_bib0030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.03.015_bib0035","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2017.03.015_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.urolonc.2015.03.021","article-title":"The development of abiraterone acetate for castration-resistant prostate cancer","volume":"33","author":"Grist","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0045","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/nyas.12846","article-title":"Development of enzalutamide for metastatic castration-resistant prostate cancer","volume":"1358","author":"Bhattacharya","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.euf.2017.03.015_bib0050","first-page":"167","article-title":"Statins and cancers","volume":"19","author":"Stryjkowska-G\u00f3ra","year":"2015","journal-title":"Contemp Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0055","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.ejca.2011.01.005","article-title":"Statins and prostate cancer: molecular and clinical aspects","volume":"47","author":"Papadopoulos","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2017.03.015_bib0060","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ctrv.2015.04.005","article-title":"Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies","volume":"41","author":"Zhong","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2017.03.015_bib0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/EDE.0000000000000189","article-title":"Statin use after diagnosis of breast cancer and survival: a population-based cohort study","volume":"26","author":"Cardwell","year":"2015","journal-title":"Epidemiology"},{"key":"10.1016\/j.euf.2017.03.015_bib0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canep.2016.10.004","article-title":"Statin use and survival in colorectal cancer: results from a population-based cohort study and an updated systematic review and meta-analysis","volume":"45","author":"Gray","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.euf.2017.03.015_bib0075","doi-asserted-by":"crossref","first-page":"e1644","DOI":"10.1097\/MD.0000000000001644","article-title":"Statin use reduces prostate cancer all-cause mortality: a nationwide population-based cohort study","volume":"94","author":"Sun","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.euf.2017.03.015_bib0080","doi-asserted-by":"crossref","first-page":"e46691","DOI":"10.1371\/journal.pone.0046691","article-title":"Statin use and risk of prostate cancer: a meta-analysis of observational studies","volume":"7","author":"Bansal","year":"2012","journal-title":"PLoS One"},{"issue":"18","key":"10.1016\/j.euf.2017.03.015_bib0085","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/sj.onc.1202322","article-title":"Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53","volume":"17","author":"Rao","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.euf.2017.03.015_bib0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ctrv.2004.06.010","article-title":"Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer","volume":"30","author":"Graaf","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2017.03.015_bib0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1756-9966-29-127","article-title":"Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho\/Rho-associated coiled-coil-containing protein kinase pathway","volume":"29","author":"Kidera","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.euf.2017.03.015_bib0100","first-page":"219","article-title":"Cholesterol accumulation in prostate cancer: a classic observation from a modern perspective","volume":"1835","author":"Krycer","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.euf.2017.03.015_bib0105","doi-asserted-by":"crossref","first-page":"e30062","DOI":"10.1371\/journal.pone.0030062","article-title":"Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors","volume":"7","author":"Mostaghel","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2017.03.015_bib0110","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JCO.2013.49.4757","article-title":"Use of statins and the risk of death in patients with prostate cancer","volume":"32","author":"Yu","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0120","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/pros.22907","article-title":"Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer","volume":"75","author":"Song","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2017.03.015_bib0125","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1464-410X.2010.09232.x","article-title":"Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE","volume":"106","author":"Katz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2017.03.015_bib0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2013.01.007","article-title":"Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease","volume":"65","author":"Grytli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2017.03.015_bib0135","first-page":"184297","article-title":"Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy?","author":"Caon","year":"2014","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.euf.2017.03.015_bib0140","doi-asserted-by":"crossref","first-page":"e0161959","DOI":"10.1371\/journal.pone.0161959","article-title":"Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate","volume":"11","author":"Boegemann","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.euf.2017.03.015_bib0145","first-page":"1689","article-title":"Statin use and mortality of patients with prostate cancer: a meta-analysis","volume":"9","author":"Meng","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.euf.2017.03.015_bib0150","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2015.58","article-title":"Association between statins and clinical outcomes among men with prostate cancer: a systematic review and meta-analysis","volume":"19","author":"Raval","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euf.2017.03.015_bib0155","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1111\/j.1464-410X.2012.11527.x","article-title":"Statin use and the risk of biochemical recurrence of prostate cancer after definitive local therapy: a meta-analysis of eight cohort studies","volume":"111","author":"Scosyrev","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2017.03.015_bib0160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.diabres.2016.07.026","article-title":"Rosuvastatin decreases testosterone levels but not sexual function in men with type 2 diabetes","volume":"120","author":"Hsieh","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.euf.2017.03.015_bib0165","doi-asserted-by":"crossref","first-page":"40085","DOI":"10.18632\/oncotarget.9485","article-title":"Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study","volume":"7","author":"Verzoni","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2017.03.015_bib0170","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2015.0829","article-title":"Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer","volume":"1","author":"Harshman","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2017.03.015_bib0175","first-page":"1924","article-title":"Alterations of p53 are common in early stage prostate cancer","volume":"10","author":"Downing","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.euf.2017.03.015_bib0180","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ncb3427","article-title":"DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway","volume":"18","author":"Parrales","year":"2016","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.euf.2017.03.015_bib0185","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamainternmed.2015.0289","article-title":"Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial","volume":"175","author":"Kutner","year":"2015","journal-title":"JAMA Intern Med"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917300834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456917300834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:47:46Z","timestamp":1762498066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456917300834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S2405456917300834"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2017.03.015","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2017.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}